Multilesion angioplasty: Progress and a plea for proof  by Ryan, Thomas J.
JACC Vol. 13, No. 2 
February 1989:289-90 
289 
Editorial Comment 
Multilesion Angioplasty: Progress vessel closure of 3%. This figure is enviably low and com- 
and a Plea for ProoF 
pares favorably with that seen in patients undergoing single 
lesion angioplasty (3,4). As have others, Gaul et al. found 
that a large intimal tear and hypotension were predisposing 
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factors to abrupt vessel closure. Although they do not 
provide clinical or lesion-specific data similar to those of a 
Boston, Massachusetts recent consensus report (5), they do underscore that, in 
multivessel dilations, 80% of the abrupt vessel closures 
occur in the first artery dilated when hypotension is induced 
Abrupt vessel closure occurring in relation to percutaneous 
transluminal coronary angioplasty (PTCA) has been recog- 
nized as one of the main risks of the procedure ever since it 
was first introduced as an alternative form of myocardial 
revascularization over a decade ago. Back then, coronary 
angioplasty was used predominantly to treat symptomatic 
patients with discrete, proximal, noncalcified, subtotal oc- 
clusive lesions in a single coronary artery. Procedural suc- 
cess averaged 61% in these patients whereas the in-hospital 
untoward event rate approached 10%. Patients either died in 
the hospital (1.2%) or left after having had a documented 
myocardial infarction (5.0%~) or emergency bypass surgery 
(5.8%) (I). 
With experience and technical skill gained over time, 
coupled with major advancements in catheter systems, pro- 
cedural success has improved substantially and angioplasty 
is now undertaken in patients with multivessel disease and 
those with multiple stenoses in the same vessel. It is encour- 
aging that, despite a recognized change in the case mix to 
more complex cases in recent years, the in-hospital rate of 
nonfatal myocardial infarction has decreased to 4.3% and the 
use of emergency bypass surgery has declined to 3.4%; the 
mortality rate remains unchanged at I .O% (1). 
Although some of this morbidity and mortality is attrib- 
utable to the procedure that fails immediately because of 
dissection at the time the stenotic lesion is crossed with the 
catheter balloon system, the real nemesis continues to be the 
unpredictable event of abrupt vessel closure after an initially 
successful dilation. 
Present study. In this issue of the Journal (2), Gaul and 
his colleagues at the Cleveland Clinic offer a careful analysis 
of their experience with acute occlusion in multiple lesion 
coronary angioplasty. Twenty percent of their first 3,500 
patients undergoing angioplasty had multiple lesions dilated 
during a single session with an incidence rate of abrupt 
during the second vessel attempt. Quite-wisely, they recom- 
mend staging the procedure “to another day” if the first 
angioplasty results in a large intimal tear or the patient is 
relatively hypotensive. 
Less than clear, however, is their position that “patients 
with multivessel disease undergoing multivessel angioplasty 
on separate days as single vessel attempts are not considered 
multivessel angioplasty.” In recommending staged proce- 
dures for multivessel angioplasty, there are not only valid 
questions about cost but also critical questions about time. 
The interval between staged procedures should be deter- 
mined by more precise knowledge of the rate of vessel repair 
after the known trauma associated with successful balloon 
dilation. This is not likely to occur for many days or even 
weeks, and safety may not be served by simply waiting until 
“tomorrow.” If multivessel angioplasty is to reach its full 
promise, it would seem far more sensible to identify the 
complex lesions, dilate them first and then proceed to the 
lower risk lesions for subsequent attempts. In the absence of 
a large intimal tear or an unstable condition, there would 
seem to be little to no justification for staging multilesion 
angioplasties. 
Supporting this contention is the equally impressive fact 
that only one-half of the patients experiencing abrupt vessel 
closure in the Cleveland Clinic study developed a Q wave 
infarction or required emergency bypass surgery. These 
findings translate into an untoward event rate of 1.5%. 
Although these incredibly good results stand as testimony to 
the procedural skills of the individuals involved, the data 
also reflect careful patient selection at this particular institu- 
tion for this form of revascularization. This is an important 
point not to be overlooked by those enthusiasts who tend to 
generalize specific data and who might, as a result of this 
article, embrace all multivessel angioplasty as being associ- 
ated with a very low risk. It will not escape the critical reader 
that 51% of this patient population had single vessel disease 
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and that among the remaining 49% categorized as having 
reflect the views of the authors and do not necessarilv reuresent the views of multivessel disease, there is a strong likelihood that the 
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only 1 of the IO patients with multivessel disease who 
experienced abrupt vessel closure was undergoing dilation of 
81989 by the American College of Cardiology 0:35-1097iK9/$3.so 
290 RYAN 
EDITORIAL COMMENT 
JACC Vol. 13, No. 2 
February 1989:289-90 
three separate coronary vessels. This point has little bearing 
on the thrust of the article of Gaul et al. but reinforces a 
sense that the burgeoning business of multivessel angio- 
plasty may primarily involve the “two vessel disease 
market.” 
Implications. Except for patients with unstable or severe 
angina, there is only scant evidence that surgical revascular- 
ization substantially improves the outcome of patients with 
anything less than three vessel diseases (6,7). There is little 
reason to believe that revascularization by angioplasty will 
do any better, or even as well, in this rather low risk group. 
It becomes increasingly evident that the cardiology commu- 
nity must quickly bring to completion a number of random- 
ized clinical trials* now under way to compare the efficacy, 
safety and cost-effectiveness of coronary angioplasty and 
coronary bypass surgery in patients with multivessel dis- 
*Funded by the National Heart, Lung, and Blood Institute, National 
Institutes of Health, Bethesda, Maryland: Bypass Angioplasty Revasculariza- 
tion Intervention (BARI) (Chairman: Robert Frye, MD, Rochester, Minne- 
sota); Emory Angioplasty or Surgery Trial (EAST) (Chairman: Spencer King, 
MD, Atlanta, Georgia). In Europe: Coronary Angioplasty Bypass Revascu- 
larization Investieation (CABRI) (Chairman: Michel Bertrand, MD. Lille. 
France): Randomized InterventionTrial of Angina (RITA) (Chairman: Edgar 
Sowton, MD, London, England); Coronary Angioplasty versus Bypass Sur- 
gery in Patients with Multivessel Disease (Chairman: Walter Bleifeld, MD, 
Hamburg, West Germany). 
ease. This can only be done successfully if clinicians are 
willing to freely enter all qualifying patients with the convic- 
tion that revascularization is indicated and without the 
impediment of clinical bias that suggests that they already 
know the answer. In the meantime there are lessons to be 
learned from sound observational studies such as the one by 
Gaul et al. (2) 
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